Dose: 0.09 mg/kg/day
Single Dose: 0.09 (0.09)
Frequency: As recommended.
Route: IV
Instructions: Should be given for 7 consecutive days.

2-CdA, 2-CdA are the derivatives of Cladribine. It is of Synthetic origin. . The Molecular Weight of Cladribine is 285.69.

Cladribine is contraindicated in conditions like Hypersensitivity to any component of product.

The severe or irreversible adverse effects of Cladribine, which give rise to further complications include Bleeding, Dizziness.The symptomatic adverse reactions produced by Cladribine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Vomiting, Constipation, Loss of appetite.

Cladribine is primarily indicated in conditions like Hairy cell leukaemia, Neutropenia, Thrombocythaemia, and can also be given in adjunctive therapy as an alternative drug of choice in Histiocytosis, Multiple sclerosis.

No data regarding the interactions of Cladribine was found.

Liver Function Test (LFT)

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Protect from Sunlight.

is a potent antineoplastic agent with potentially significant toxic side effects. It should be administered only under the supervision of a physician experienced with the use of cancer chemotherapeutic agents. Patients undergoing therapy should be closely observed for signs of hematologic and non-hematologic toxicity. Periodic assessment of peripheral blood counts, particularly during the first 4 to 8 weeks post-treatment, is recommended to detect the development of anemia, neutropenia and thrombocytopenia and for early detection of any potential sequelae (e.g., infection or bleeding).